Compile Data Set for Download or QSAR
maximum 50k data
Found 15 of ic50 for monomerid = 253941
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Gi Therapeutics

US Patent
LigandPNGBDBM253941(US9464092, GG | US9527857, GG)
Affinity DataIC50:  1nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Gi Therapeutics

US Patent
LigandPNGBDBM253941(US9464092, GG | US9527857, GG)
Affinity DataIC50:  1nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Gi Therapeutics

US Patent
LigandPNGBDBM253941(US9464092, GG | US9527857, GG)
Affinity DataIC50:  1nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Gi Therapeutics

US Patent
LigandPNGBDBM253941(US9464092, GG | US9527857, GG)
Affinity DataIC50:  1.06nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Gi Therapeutics

US Patent
LigandPNGBDBM253941(US9464092, GG | US9527857, GG)
Affinity DataIC50:  1.06nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-A2/Cyclin-dependent kinase 2(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253941(US9464092, GG | US9527857, GG)
Affinity DataIC50:  1.51nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253941(US9464092, GG | US9527857, GG)
Affinity DataIC50:  3.58nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D3(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253941(US9464092, GG | US9527857, GG)
Affinity DataIC50:  4.70nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-H/Cyclin-dependent kinase 9(Homo sapiens (Human))
Eli Lilly

Curated by ChEMBL
LigandPNGBDBM253941(US9464092, GG | US9527857, GG)
Affinity DataIC50:  280nMAssay Description:Inhibition of CDK9/cyclin H (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-A1/Cyclin-dependent kinase 2(Homo sapiens (Human))
Gi Therapeutics

US Patent
LigandPNGBDBM253941(US9464092, GG | US9527857, GG)
Affinity DataIC50:  1.51E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-A2/Cyclin-dependent kinase 2(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253941(US9464092, GG | US9527857, GG)
Affinity DataIC50:  1.51E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-A2/Cyclin-dependent kinase 2(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253941(US9464092, GG | US9527857, GG)
Affinity DataIC50:  1.51E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253941(US9464092, GG | US9527857, GG)
Affinity DataIC50:  3.58E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253941(US9464092, GG | US9527857, GG)
Affinity DataIC50:  3.58E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253941(US9464092, GG | US9527857, GG)
Affinity DataIC50:  3.58E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails US Patent